ORIGINAL RESEARCH

OCULAR MANIFESTATIONS OF BEHCET'S DISEASE
AN ANALYSIS OF 133 MOROCCAN PATIENTS

Dr Alami F ; Dr El berdaoui N; Dr Imdary I ; Pr Benckhroun N ; Pr Hajji Z; Pr Berraho A
Department of Ophthalmology A, Rabat Specialities Hospital, Ibn Sina University Hospitals, UM5S, Rabat, Morocco.

Received 15 December, 2013; Revised 16 Mars 2014; Accepted 06 April 2014

ABSTRACT:
Introduction: Behcet’s disease is a systemic disorder linked to occlusive vasculitis and of a relatively unknown pathogenesis. Ocular manifestations of the disease mainly comprise uveitis in 60-80% of cases, followed by retinal vasculitis and then retinal vein occlusion. The aim of this study is to analyze ocular manifestations of patients with confirmed Behcet’s disease, their complications, treatment and evolution in our tertiary care unit of Morocco.

Patients and methods: It is a retrospective study of patients with confirmed Behcet along with ocular manifestations, hospitalized in the department of ophthalmology at the teaching hospital of Rabat from June 2002 to June 2012.

Results: A total of 133 patients were included in the study, being 29.5 years-old on average. Visual acuity is very low before treatment: 56% had less than 1/10. Ocular manifestations included mainly uveitis with 89.96%, followed by retinal vasculitis 73.6% and maculopathy 22%. The percentage of the eyes of which the VA was inferior to 1/10 became 35.9% after the treatment.

Conclusion: The most frequent clinical presentation in our context is a total uveitis with a posterior predominance associated with a vasculitis. Pupillary seclusion is the most frequent complication. Corticotherapy and immunosuppressive drugs are the therapeutic methods used the most in our context.

Keywords: Behcet’s disease, uveitis, vasculitis, treatment.

Corresponding author:
Dr Fadoua Alami: Department of Ophthalmology A, Rabat Specialities Hospital, Ibn Sina University Hospitals, UM5S, Rabat, Morocco.
Email: alamifadoua@gmail.com

Copyright © 2014 Fadoua Alami et al.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION
First described in 1937 [1], Behcet’s disease is an idiopathic, multisystem inflammatory chronic relapsing disorder, systemic occlusive vasculitis, which affects veins and arteries of all sizes, characterized by recurrent oral aphthous ulcers, genital ulcers, skin lesions, and both anterior and posterior uveitis [2-4]. International Study Group for Behcet’s Disease (ICBD) established diagnostic criteria for Behcet’s disease; ocular lesions, oral aphthous ulcerations, and genital aphthous ulcerations are each assigned 2 points, while skin lesions, central nervous system involvement, and vascular manifestations are assigned 1 point each. The pathergy test, when used, was assigned 1 point. A patient scoring ≥4 points is classified as having Behcet’s disease [5, 6]. Ocular inflammation occurs in approximately 70% of patients and is associated with high risk of blindness [7]. Ocular inflammation as a result of irreversible, progressive, ischemic damage of the retina,
and optic disc, commonly leads to severe panuveitis and its complications [4, 7, 8]. It can be inaugural, habitually bilateral and develops through episodes of remissions [9, 10]. Cataract, secondary glaucoma, optic disc atrophy, and macular edema are the most common complications in Behcet’s disease leading to decrease of vision [11, 12]. The aim of this study is to analyze ocular manifestations of patients with confirmed Behcet’s disease, their complications, treatment and evolution in our tertiary care unit of Morocco.

**MATERIAL AND METHODS**

It is a retrospective monocentric study of 133 patients with Behcet’s disease, hospitalized in the Department of Ophthalmology in the Teaching Hospital of Rabat between June 2002-2012 and presented with an ocular disease. Only patients whose diagnostic criteria of the International Study Group (ISG) were complete were kept, non-hospitalized and lost to follow-up patients were excluded in our study. “Epi info” was used for the statistical analysis. Information was collected after consent of patient through a prior patient’s chart stating the following parameters: age, sex, date of the ocular inflammation onset in relation to the date of behcet’s disease diagnosis, ophthalmological signs and data of the initial ophthalmological examination (visual acuity, slit-lamp examination, and fundus photography). All patients have benefitted from: Complete ophthalmic examination; Retinal fluorescein angiography as soon as ocular environments allowed it. +/- Visual field, ERP- ERG, Ocular echography, OCT. Implemented therapeutics was noted as well as the changing profile of the ocular inflammation. Existence of ocular complications was noted. The number of episodes, cause of recurrences and relapses were also reported.

**RESULTS**

**Epidemiology:**

Average age at the time of the occurrence of the ocular inflammation in our list is 22.40 years-old +/- 3.2 with extremes between 10 and 54 years-old. Net predominance of males 76.1% (n=101) with a sex ratio of 3.16 (p < 0.05). Ocular inflammation reveals the disease in 6.12% of cases (n=8).

**Visual acuity:**

At the time of diagnosis, 18 patients (6.8% of eyes) were monophthalmus. Initial visual acuity was: ≤1/10 in 56.46% of cases (n=75), between 1- 5/10 in 20.5% (n=27), and ≥ 5/10 in 16.3% (n=21).

**Anterior segment inflammation:**

Panuveitis is the most frequent inflammation, found in 40.93% (n=54) of patients whereas anterior uveitis was present in only 10.67% (n=14) of cases, among them 4% (n=5) with hypopyon (Figure 1a, b). Posterior segment inflammation (Figure 2a, b, c, d). Posterior segment inflammation is the most frequent 38.27% (n=50). Intermediate uveitis found in 10.13% (n=13). Retinal vasculitis found in 73.6% (n=97).
Complications: (Table 1)
Complications were observed in 43.4% of cases (n=57).
The most frequent ones were:
- Macular edema, diffused in 22% of cases (n=29), conditioning the long-term visual prognosis, its diagnosis and supervision relies on the clinical examination, angiography and OCT. Macular edema is less frequent in our list (n=19), usually posterior subcapsular cataract.
- Optic atrophy and glaucoma in 10% (n=13) of cases.

| Type of inflammation | Prevalence (%) |
|----------------------|----------------|
| Cataract             | 19.6           |
| Retinal detachment   | 4.7            |
| Macular degeneration | 18.7           |
| Macular hole         | 3.7            |
| Pupillary seclusion  | 20.6           |
| Optic atrophy        | 6.5            |
| Neovascular glaucoma | 4.7            |
| Ocular hypertonia    | 16.8           |
| Vitreous organization| 2.8            |
| Phthisis bulbi       | 1.9            |

Table 1: prevalence of the occurrence of main complications.

Treatment:
The deadline to start treatment was one year among more than 7% of our patients (n=93) with an average number of cures of 7.5 during the first year and of an average treatment duration of 4.1 years. Topical mydriatic and cycloplegic treatment to prevent or cure iridocrystalline synechias, and resting the eye.

Corticotherapy given to all patients:
- Topical in case of anterior uveitis: Bolus of methylprednisolone (10mg/Kg/day) during three days with a shift by oral route (1mg/Kg/day) with a progressive tapering with a palliation of 10% every 1-2 weeks associated with sodium-restricted and hypocaloric regimen, potassic supplementation, vitamin D and Calcium.
- Laterobulbar injection of triamcinolone acetonides: 10 eyes
- Sub-Tenons injections of triamcinolone: 3 eyes
- Immunosuppressive drugs:
  - Sub-Tenons injections of cyclophosphamide: 20% (n=26) and azathioprine: 1.2% (n=1).

After an average decline of 4.2 years, final visual acuity was <1/10 in 35.9% (n=94) of eyes and ≥ 5/10 in 38.5% (n=102) of eyes.

| Initial VA | Final VA |
|------------|----------|
| ≤1/10      | 35.9%    |
| 1/10-5/10  | 20.5%    |
| ≥ 5/10     | 16.3%    |

Table 2: Evolution of visual acuity

DISCUSSION
Behcet’s disease is multisystemic vasculitis, characterized by remissions and exacerbations.

Male predominance in our list was not found in others: Male to female ratio was 0.98 in Japan, 1.19 in Iran, 1.03 in Turkey, and 1.8 in India [4, 13]. We note this net predominance of symptomatic and severe features among males [14-16].

Young patients were the ones affected the most as in our case. The average age found in our study was similar to other reports with 35.7 in Japan, 29 in Korea, 26 in Iran, 25.6 in Turkey, 29 in Greece, 24.5 in Germany, and 24.7 in UK [4, 13].

The severity of the ocular inflammation seems inversely proportional at the age [17]. The incidence of ocular inflammation in Behcet’s disease is reported to be 70% [18] and is among the main criteria of Behcet’s disease according to ISG (Table 3).

| Recurrent oral ulceration | Minor aphthous, major aphthous or herpitiform ulceration observed by physician or patient, which have recurred at least three times in a 12-month period |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| And two of the following |                                                                                                                                  |
| Recurrent genital ulceration | Aphthous ulceration or scarring, observed by physician or patient                                                                   |
| Eye lesions               | Anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination; or retinal vasculitis observed by ophthalmologist |
| Skin lesions              | Erythema nodosum observed by physician or patient, pseudofolliculitis or papulopustular lesions; or acneiform nodules observed by the physician in post-adolescent patients not on corticosteroid treatment |
| Positive pathergy test    | Read by physician at 24-48 hours                                                                                                  |

Table 3: International study group criteria for the diagnosis of Behcet’s disease [5].

Ocular inflammation revealed BD in 6.12% of our cases.

In our list, ocular inflammation revealed MB in 8 patients (68 %). In literature, this inflammation can be inaugural in 8-71% of cases [19-21]. There are cases of Behcet’s disease without ocular manifestations [4]. Usually, it is initially unilateral. However, bilateralism of lesions seems ineluctable in the absence of treatment and occurs in the first two or three years after the onset of the disease [22].
Complicated cataract is found in 21-36% of cases according to literature [9]. Corticosteroids can favor its evolution and that of inflammatory glaucoma. Maculopathy is frequent, observed in 16-50% cases in our study, and 23.6% in our study; local corticosteroid therapy can favor its evolution and that of inflammatory glaucoma.

Optic nerve inflammation during Behcet’s disease is relatively frequent and serious [28], 3.6% of our patients developed optic atrophy. Treatment of ocular inflammatory of Behcet’s disease has not been standardized yet. Corticosteroids are commonly used as anti-inflammatory agents for the treatment of the majority of Behcet’s disease manifestations. Acute and severe disease exacerbations of anterior (poorly responsive to topical/periorcular corticosteroid) or posterior, or panuveitis as well as retinitis should be treated with higher doses of systemic corticosteroid to offer a rapid response. Oral (prednisolone, 1-2mg/kg/daily or 60–120mg/daily, given in a single morning dose after meals) or intravenous route as pulse methylprednisolone (1 g/daily for three consecutive days) is preferred particularly if bilateral process exists [11, 12, 29]. Numerous authors agree to rapidly use immunosuppressive drugs, either immediately or according to the seriousness or bilaterality of lesions [19].

Cyclosporine A is the most rapidly acting agent for acute uveitis at a daily initial dosage of 5mg/kg, and combined therapy with azathioprine is more effective than monotherapy [12]. Besides systemic cyclosporine A and corticosteroid therapy in treatment of severe forms of uveitis, cystostatic drugs such as azathioprine (50–150mg/daily), methotrexate (7.5–25mg/week), and colchicine (1-2mg/daily) are effective in controlling the attacks of posterior ocular inflammation and vasculitis, improving the long-term visual prognoses of the disease with prevention of new eye disease [12, 30]. Visual prognostic is conditioned essentially by papillomacular involvement. Visual loss may also develop as a result of retinal vasculitis and its complications, such as macular edema and others. Typically, patients have episodes of severe uveitis and retinal vasculitis that progressively damaged vision [4]. young age, male sex, and late care are elements of a bad prognosis [9].

In our context, late consultation and therefore a late care of the ocular inflammation worsen the prognosis: 18 eyes (6.8%) had no light perception during the firsts hospitalization. Although we resorted to immunosuppressive drugs, final visual acuity remained below <1/10 in 35.9 % of cases.

CONCLUSION
Behcet’s disease is frequent in Morocco, and is about 24% of all uveitis and 34% of serious uveitis. The most frequent clinical presentation in our context is a total uveitis with a posterior segment predominance associated with a vasculitis. The most frequent complication in our context is Pupillary seclusion. Treatment comprises always corticosteroid and immunosuppressive drugs in 73.45% of cases. Infliximab, anti – TNF- alpha is an advance in the treatment of behcet’s disease. Ocular inflammation is severe, requiring a strong collaboration between the ophthalmologist and internist in terms of heavy treatments associating general corticotherapy and immunosuppressive drugs.

ABBREVIATION
ICBD International Study Group for Behcet’s Disease
ISG International Study Group

SOURCE OF SUPPORT
Declared none.

COMPETING INTERESTS
The authors declare no competing interests.

AUTHORS’ CONTRIBUTIONS
The participation of each author corresponds to the criteria of authorship and contributorship emphasized in the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals of the International Committee of Medical Journal Editors. Indeed, all the authors have actively participated in the redaction, the revision of the manuscript and provided approval for this final revised version.

ACKNOWLEDGEMENT
Declared none.

REFERENCES
[1] H B. Über rezidivierende phthise, durch ein virus verursachte geschwure am mund, am auge und an den genitalien. Dermatologische Wochenschrift.36:1152–7.
[2] Mendes D, Correia M, Barbudo M, Vaio T, Mota M, Gonçalves O, et al. Behcet's disease–a contemporary review. Journal of autoimmunity. 2009;32(3):178-88.
[3] Pleyer U, Haizrolan D, Winterhalter S, Stübiger N. Behcet's disease—ophthalmological and general aspects part I: etiology, pathogenesis and diagnostics. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012;109(11):1129.

[4] Paovic J, Paovic P, Sredoovic V. Behcet's Disease: Systemic and Ocular Manifestations. BioMed Research International. 2013;7:7.

[5] Davatchi F, Assaad-Khalil S, Calamia K, Crook J, Sadeghi-Abdollahi B, Schirmer M, et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology. 2013.

[6] Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. 1990;335(8697):1078-80.

[7] Durrani K, Ahmed M, Foster CS. Adamantiades-Behçet disease: diagnosis and current concepts in management of ocular manifestations. Comprehensive ophthalmology update. 2007;8(4):225-33.

[8] Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H. Ocular features of Behçet's disease: an international collaborative study. British Journal of Ophthalmology. 2007;91(12):1579-82.

[9] Hagi Z, Berraho A. Éil et maladie de Behçet. EMC Ophthalmologie. 2003;21-225-C-20.

[10] Khairallah M, Ben Yahia S, Kahloun R, Khairallah-Ksiaa L, Messaoud R. [The eye and Behçet's disease]. Journal francais d'ophtalmologie. 2012;35(10):826-37.

[11] Stubiger N, Pleyer U. [Typical and atypical ocular manifestations of Behçet's disease]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012;109(6):558-62.

[12] Paovic J, Paovic P, Sredovic V. Correlation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behçet's Disease. Autoimmune Diseases. 2013;2013:7.

[13] Davatchi F, Shahram F, Chams C, Nadji HCA. Behcet's disease. Acta Medica Iranica. 2005;43(4).

[14] Benamour S, Zeroual B, Bennis R, Amraoui A, Bettal S. [Behcet's disease—316 cases]. Presse medicale (Paris, France 1983). 1990;19(32):1485-9.

[15] Ghayad E, Tohme A. [Behcet disease in Lebanon]. Revue du rhumatisme (Ed francaise : 1993). 1994;61(4):287-8.

[16] Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunas B, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373-80.

[17] Kone-Paut I. [Behcet's disease: pediatric features]. Annales de medecine interne. 1999;150(7):571-5.

[18] Chiheb S, Chakib A, Lakhdar H. [Behçet's disease]. Annales de dermatologie et de venereologie. 2003;130(6-7):657-63.

[19] Janati K, K ELO, Benchikh H, Hamdani M, Lakhdar H. [Ocular manifestation of Behçet disease (study of 50 patients consulting in dermatology department)]. La Revue de medecine interne / fondée par la Société nationale francaise de médecine interne. 2005;26(10):771-6.

[20] Filali-Ansary N, Tazi-Mezalek Z, Mohattane A, Adnaoui M, Aouni M, Maouni A, et al. [Behçet disease. 162 cases]. Annales de medecine interne. 1999;150(3):178-88.

[21] Zierhut M, Saal J, Pleyer U, Kotter I, Durk H, Fierlein G. Behçet's disease: epidemiology and eye manifestations in German and Mediterranean patients. German journal of ophthalmology. 1995;4(4):246-51.

[22] el Belhadj M, Hamdani M, Louissi N, Zaghoul K, Amraoui A, Benamour S. [Ophthalmological involvement in Behçet disease. Apropos of 520 cases]. Journal francais d'ophtalmologie, 1997;20(8):592-8.

[23] Hamza M, Meddeb S, Mili I, Ouerhani A. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Behçet's disease. Preliminary results with the use of new criteria of evaluation]. Annales de medecine interne. 1992;143(7):438-41.

[24] Cochereau-Massin I, Wechsler B, Le Hoang P, Le Thi Huong D, Girard B, Rousselie F, et al. [Ocular prognostic in Behçet's disease]. Journal francais d'ophtalmologie. 1992;15(5):343-7.

[25] Atmaca LS. Fundus changes associated with Behçet's disease. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 1989;227(4):340-4.

[26] Daghlous MT, Ammar M, Kamoun M, Triki F. [Clinical aspects and course of Adamantiades-Behçet disease in Tunisia: a report on 41 cases (author's transl)]. Journal francais d'ophtalmologie. 1980;3(8-9):463-8.

[27] Benchekroun O, Lahbli D, Lamari H, Rachid R, El Belhadi M, Louissi N, et al. [Macular damage in Behçet's disease]. Journal francais d'ophtalmologie. 2004;27(2):154-9.

[28] Lamari H, Baha AT, Benhaddou M, Alikane O, Hamdani M, Zaghoul K, et al. [Involvement of the optic nerve in the course of Behçet's disease (presentation of 148 cases)]. Bulletin de la Societe belge d'ophthalmologie. 2003;289(9-14).

[29] Deuter CM, Zierhut M, Doycheva D, Kötter I. [Treatment of Behçet's disease yesterday and today]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012;109(6):568-74.

[30] Kaklamani VG, Kaklamani PG. Treatment of Behçet's disease—An update. Seminars in arthritis and rheumatism. 2001;30(5):299-312.